Business News • PR NewsWire • BioSpecifics Technologies Corp. Announces Commencement of European Regulatory Review of XIAFLEX(TM) for the Treatment of Dupuytren's Disease

BioSpecifics Technologies Corp. Announces Commencement of European Regulatory Review of XIAFLEX(TM) for the Treatment of Dupuytren's Disease

BioSpecifics Technologies Corp. Announces Commencement of European Regulatory Review of XIAFLEX(TM) for the Treatment of Dupuytren's Disease

LYNBROOK, N.Y., Jan. 21 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from th

View More : http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-announces-commencement-of-european-regulatory-rev...

Releted News by prnewswire

Eastbridge Al Mal Holdings Formed By a Kuwait Investment Company to Invest in U.S. Real Estate Opportunities

Broadstripe Enhances Digital Home Phone Service, Adds Free Voice Mail and Calls to Canada